EQUAL: Asya ve Latinx Popülasyonlarında Akciğer Kanseri Taraması İçin EGFR ctDNA Nicel Değerlendirmesi

Sade dilde özet

Bu çalışma, Asya ve Latinx kökenli, sigara kullanmayan bireylerde akciğer kanserinin (lung cancer) erken taraması için kanda dolaşan tümör DNA'sını (ctDNA) ölçen EGFR temelli bir testi incelemektedir. Doğu/Güneydoğu Asyalı ya da Hispanik/Latinx olarak kendini tanımlayan, belirli yaş ve risk ölçütlerini karşılayan ve hâlihazırda sigara içmeyen kişiler dahil edilebilmektedir. Çalışma faz uygulanmayan bir çalışma olup halen katılımcı almaktadır.

Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.

Deney bilgileri

Faz

Faz dışı

Durum

Katılımcı alıyor

Sponsor

Dana-Farber Cancer Institute

Müdahale

Circulating Tumor DNA (ctDNA) Assay

Başlangıç

01.04.2025

Tahmini bitiş

01.09.2030

Ülkeler

United States

İlgili genler

Merkezler

• Boston, United States
• Boston, United States
• Boston, United States
• Brighton, United States
• Methuen, United States
• South Weymouth, United States

Uygunluk kriterleri

Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.

Inclusion Criteria (Aims 1, 2, and 3) for Group 1 (50 through 80 years of age):

* Non-tobacco using (currently)
* Self-identify as East Asian (including Southeast Asian) or Hispanic/Latinx.
* East Asian includes those who self-identify as Chinese, Japanese, Korean, Taiwanese, Malaysian
* Southeast Asian includes those who self-identify as Cambodian, Thai, Vietnamese, Filipino
* Latinx includes those who self-identify as a person of Central or South American and the Caribbean including, Cuban, Puerto Rican, and Dominican culture or origin, excluding individuals originating from Spain
* Aims 1 and 2: Able to complete and understand the study's informed consent in English, Mandarin, Cantonese, Japanese, Korean, Vietnamese, Spanish, Portuguese, or Cape Verdean
* Aim 3: Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish.

Inclusion Criteria (Aims 1, 2, and 3) for Group 2 (40 through 49 years of age):

* Non-tobacco using (currently)
* Self-identify as East Asian (including Southeast Asian) or Latinx, if any of the following criteria are met:

  * Family history of EGFR positive LC L858R or exon 19
  * Personal history of remote cancer that is not LC or other thoracic malignancies, including thymoma, thymic carcinoma, or sarcoma, as long as it was resolved over 5 years ago
  * History of TB, asthma requiring daily inhaled corticosteroids or chronic bronchitis
  * Symptoms of lung cancer for the past month, including hemoptysis, unexplained weight loss, voice hoarseness, cough or worsening cough, dyspnea or worsening dyspnea
* Excluding individuals who concurrently present with fever, covid/influenza/RSV/adenovirus infection, runny nose, sore throat, productive cough with green or yellow sputum
* Aims 1 and 2: Able to complete and understand the study's informed consent in English, Mandarin, Cantonese, Japanese, Korean, Vietnamese, Spanish, Portuguese, or Cape Verdean
* Aim 3: Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish.

Exclusion Criteria (Aims 1, 2, and 3) for Groups 1 and 2:

* Having had a chest CT scan in the last 3 years or having an anticipated chest CT scan during the enrollment period.
* Having a current cancer or history of cancer within the last 5 years, excluding localized non-melanoma skin cancer and breast ductal carcinoma in situ.
* More than 400 lifetime cigarettes (i.e., 20 packs) of smoking or tobacco use
* Adults unable to provide informed consent
* Individuals \<40 years of age
* Prisoners
* Pregnant women
* Personal diagnosis of lung cancer
* Not able to be compliant with study requirements